BFM
TERN

Boothbay Fund Management’s Terns Pharmaceuticals TERN Stock Holding History

Boothbay Fund Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
+4,600
New +$189K ﹤0.01% 1719
2023
Q4 		– Sell
-40,300
Closed -$203K – 1982
2023
Q3 		$203K Hold
40,300
– – ﹤0.01% 1433
2023
Q2 		$353K Buy
+40,300
New +$470K 0.01% 1245

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Boothbay Fund Management's TERN Position: Q1 2026 in Review

Boothbay Fund Management increased its Terns Pharmaceuticals (TERN) stake by 8.8% in Q1 2026, buying an estimated $1.61M and bringing the position to 486,170 shares worth $25.6M. The position accounts for 0.33% of the portfolio, ranked #25.

Boothbay Fund Management first reported a position in TERN in Q2 2022 and has held it in 16 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Boothbay Fund Management held 486,170 shares of Terns Pharmaceuticals worth $25.6M as of Q1 2026.
  • Boothbay Fund Management bought 39,162 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.61M.
  • Terns Pharmaceuticals made up 0.33% of Boothbay Fund Management's portfolio in Q1 2026, its #25 holding.
  • Boothbay Fund Management first reported a position in Terns Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.